Biodesix (BDSX) said in a regulatory filing Friday that some stockholders are selling up to 62.2 million of their shares.
The selling stockholders include entities related to Biodesix's board directors: Westwood Management's chief executive officer Lawrence Kennedy Jr., Crabtree Partners' co-founders Jack Schuler and John Patience, as well as Birchview Capital's managing partner Matthew Strobeck, the filing showed.
Biodesix said it will not receive any proceeds from the sale.
Separately, Biodesix filed a registration statement to sell up to $250 million in securities from time to time.
The filing includes the sale of the company's common stock, preferred stock, warrants and units, as well as rights to purchase these securities.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。